Diagnostic and prognostic utility of exosomes in immunotherapy
AssigneeBoard of Regents, The University of Texas System
InventorsRaghu Kalluri, Valerie Lebleu, Jennifer Wargo
Life of this patent
Estimating the term…
Abstract
The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. It was found that responders of immunotherapeutic treatments have a higher amount of B-cell exosomes in their blood than non-responders. Aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after B-cell exosomes have been detected in a biological sample from the subject.
Claims16
A method of treating skin cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy comprising nivolumab and ipilimumab after CD20-expressing B-cell exosomes have been detected in a biological sample from the subject.
A method for predicting a response to ICB therapy in a subject having skin cancer, the method comprising:
- (a) obtaining a biological sample from the subject;
- (b) detecting the amount of CD20-expressing B-cell exosomes in the sample from the subject;
- (c) comparing the amount of CD20-expressing B-cell exosomes in the sample from the subject to a control subject that has been determined to not respond effectively to ICB therapy;
- (d) identifying the subject as likely to respond to the ICB therapy when the detected amount of CD20-expressing B-cell exosomes in the subject sample is increased compared to the control subject sample;
- and
- (e) administering ICB therapy to the subject if the subject is identified as likely to respond to the ICB therapy,
- wherein the ICB therapy comprises nivolumab and ipilimumab.
A method of detecting CD20-expressing B-cell exosomes in a subject with skin cancer, the method comprising:
- (a) obtaining a sample from the subject;
- and
- (b) detecting whether CD20-expressing B-cell exosomes are present in the sample by contacting the sample with a labeled anti-human CD20 antibody, and detecting binding between CD20-expressing B-cell exosomes and the antibody,
- wherein the subject is determined to have an increase in the amount of detected CD20-expressing B-cell exosomes in comparison to a control representing an amount of CD20-expressing B-cell exosomes in a sample from a subject that has been determined to not respond effectively to ICB therapy, or
- wherein the subject has been determined to have an amount of detected CD20-expressing B-cell exosomes that is not significantly different from or is more than a control representing an amount of CD20-expressing B-cell exosomes in a sample from a subject that has been determined to respond effectively to ICB therapy,
- wherein the ICB therapy comprises nivolumab and ipilimumab.
Dependencies are inferred from the claim text.